eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Alcon Laboratories (U.K) Limited

Pentagon Park, Boundary Way, Hemel Hempstead, Hertfordshire, HP2 7UD
Telephone: (0)871 376 1402
Fax: +44 (0)1442 341 200

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 31/03/2011
SPC ALOMIDE 0.1% w/v

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 31/03/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 6.1 - List of Excipients
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
Date of revision of text on the SPC:   08-Nov-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Update to fragment 6.1 to reflect the presence of the excipient Benzalkonium chloride.
Amendment of the date of first authorisation/renewal in section 9.
Updated on 15/11/2010 and displayed until 31/03/2011
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   08-Nov-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



In Section 4.2, Posology and method of administration, the following text is added – ‘Nasolacrimal occlusion or gently closing the eyelid after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic adverse reactions.’

 

In Section 4.4, Special warnings and precautions for use, the following text is added – ‘Patients should be advised that instillation of eye drops may initially cause discomfort or transient burning or stinging (see section 4.8). Should these symptoms persist, the patient should be advised to contact the prescribing physician.’ Also, information regarding the preservative Benzalkonium has been amended.

 

In Section 4.5, Interaction with other medicinal products and other forms of interaction, ‘Not known’ is replaced with ‘No interaction studies have been performed’ and the following text is added – ‘If more than one topical ophthalmic medicinal product is being used, the medicines must be administered at least 5 minutes apart. Eye ointments should be administered last.’

 

In Section 4.6, Pregnancy and lactation, information regarding the use of Alomide during Pregnancy and Lactation has been updated.

 

In Section 4.7, Effects on ability to drive and use machines, the text has been amended in lines with QRD.

 

In Section 4.8, Undesirable effects, the text has been amended and represented in the MedDRA Preferred table.

 

In Section 4.9, Overdose, information regarding the actions to be taken on overdose has been updated, and the following text has been added – ‘Due to the characteristics of this preparation, no toxic effects are to be expected with an ocular overdose of this product.

 

In case of accidental ingestion of doses of 0.1 mg to 10.0 mg of lodoxamide, the following side adverse effects may occur: feeling of warmth, flushing, nausea, vomiting, diaphoresis and abdominal cramping. Transient elevations of systolic and diastolic blood pressure have been noted with doses of 3.0 and 10.0 mg of oral lodoxamide, but they resolve spontaneously after a short time. Other possible adverse effects after an oral overdose are: headache, dizziness, fatigue and loose stools.

 

If accidentally ingested, efforts to decrease further absorption may be appropriate. Lavage, if the overdose has been taken within 1 hour or treatment with activated charcoal should be considered.’

 

Also, the following sentence is removed – ‘Consideration may be given by the physician to emesis in the event of accidental ingestion.’

 

 

In Section 10, Date of revision of the text, the date of revision has been updated.

Updated on 16/05/2002 and displayed until 15/11/2010
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
   lodoxamide trometamol